JP2016524914A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016524914A5 JP2016524914A5 JP2016527005A JP2016527005A JP2016524914A5 JP 2016524914 A5 JP2016524914 A5 JP 2016524914A5 JP 2016527005 A JP2016527005 A JP 2016527005A JP 2016527005 A JP2016527005 A JP 2016527005A JP 2016524914 A5 JP2016524914 A5 JP 2016524914A5
- Authority
- JP
- Japan
- Prior art keywords
- hpv
- cells
- specific
- cell population
- fragments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019202239A JP7315435B2 (ja) | 2013-07-15 | 2019-11-07 | 抗ヒトパピローマウイルス抗原ｔ細胞の調製方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361846161P | 2013-07-15 | 2013-07-15 | |
| US61/846,161 | 2013-07-15 | ||
| PCT/US2014/046478 WO2015009604A1 (en) | 2013-07-15 | 2014-07-14 | Methods of preparing anti-human papillomavirus antigen t cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019202239A Division JP7315435B2 (ja) | 2013-07-15 | 2019-11-07 | 抗ヒトパピローマウイルス抗原ｔ細胞の調製方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016524914A JP2016524914A (ja) | 2016-08-22 |
| JP2016524914A5 true JP2016524914A5 (cg-RX-API-DMAC7.html) | 2017-08-31 |
| JP6616295B2 JP6616295B2 (ja) | 2019-12-04 |
Family
ID=51257632
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016527005A Active JP6616295B2 (ja) | 2013-07-15 | 2014-07-14 | 抗ヒトパピローマウイルス抗原ｔ細胞の調製方法 |
| JP2019202239A Active JP7315435B2 (ja) | 2013-07-15 | 2019-11-07 | 抗ヒトパピローマウイルス抗原ｔ細胞の調製方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019202239A Active JP7315435B2 (ja) | 2013-07-15 | 2019-11-07 | 抗ヒトパピローマウイルス抗原ｔ細胞の調製方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (8) | US20160144018A1 (cg-RX-API-DMAC7.html) |
| EP (3) | EP3022294B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6616295B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN105452448B (cg-RX-API-DMAC7.html) |
| AU (3) | AU2014290286A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2918080A1 (cg-RX-API-DMAC7.html) |
| ES (3) | ES2773548T3 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2713333C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015009604A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10828353B2 (en) | 2015-01-31 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for T cell delivery of therapeutic molecules |
| WO2017049237A1 (en) * | 2015-09-18 | 2017-03-23 | The General Hospital Corporation Dba Massachusetts General Hospital | Personalized approach to dosage of anti-fugetactic agent for treatment of cancer |
| EP3368051A4 (en) * | 2015-10-30 | 2019-06-26 | Children's National Medical Center | GENERATION OF HPV ANTIGEN-SPECIFIC T CELLS FROM A NAIVEN T CELL POPULATION |
| US11834675B2 (en) * | 2015-12-30 | 2023-12-05 | Celgene Corporation | T lymphocyte production methods and t lymphocytes produced thereby |
| AU2017338827B2 (en) | 2016-10-03 | 2023-08-31 | Juno Therapeutics, Inc. | HPV-specific binding molecules |
| IL266209B2 (en) | 2016-10-26 | 2025-02-01 | Iovance Biotherapeutics Inc | Re-stimulation of cryopreserved infiltrating lymphocytes |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| KR20190124214A (ko) * | 2017-01-20 | 2019-11-04 | 아타라 바이오테라퓨틱스 인크. | 자가 t 세포를 사용하여 다발성 경화증을 치료하는 방법 |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| EP3635097A1 (en) | 2017-06-05 | 2020-04-15 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
| US11952408B2 (en) | 2017-10-03 | 2024-04-09 | Juno Therapeutics, Inc. | HPV-specific binding molecules |
| JP2021509586A (ja) | 2018-01-08 | 2021-04-01 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍抗原特異的ｔ細胞について濃縮されたｔｉｌ製品を生成するためのプロセス |
| US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
| CN112585276A (zh) | 2018-04-05 | 2021-03-30 | 朱诺治疗学股份有限公司 | 产生表达重组受体的细胞的方法和相关组合物 |
| US20210015869A1 (en) | 2018-04-05 | 2021-01-21 | Juno Therapeutics, Inc. | T cells expressing a recombinant receptor, related polynucleotides and methods |
| RU2020135968A (ru) | 2018-04-05 | 2022-05-06 | Джуно Терапьютикс, Инк. | T-клеточные рецепторы и модифицированные клетки, экспрессирующие |
| WO2019196088A1 (en) * | 2018-04-13 | 2019-10-17 | Syz Cell Therapy Co. | Methods of obtaining tumor-specific t cell receptors |
| WO2019210131A1 (en) | 2018-04-27 | 2019-10-31 | Iovance Biotherapeutics, Inc. | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| US12473532B2 (en) | 2018-05-10 | 2025-11-18 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| WO2020033927A2 (en) | 2018-08-09 | 2020-02-13 | Juno Therapeutics, Inc. | Processes for generating engineered cells and compositions thereof |
| JP7504891B2 (ja) | 2018-09-11 | 2024-06-24 | ジュノー セラピューティクス インコーポレイテッド | 操作された細胞組成物のマススペクトロメトリー分析のための方法 |
| JP2022506586A (ja) | 2018-11-05 | 2022-01-17 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球の産生のためのプロセスおよび免疫療法におけるその使用 |
| GB201821207D0 (en) * | 2018-12-24 | 2019-02-06 | Tcer Ab | Immunotherapy therapy |
| KR20220016475A (ko) | 2019-05-01 | 2022-02-09 | 주노 쎄러퓨티크스 인코퍼레이티드 | 변형된 ｔｇｆｂｒ2 유전자 좌에서 재조합 수용체를 발현하는 세포, 관련 폴리뉴클레오티드 및 방법 |
| CN115244173A (zh) | 2019-12-20 | 2022-10-25 | 英研生物(英国)有限公司 | 用于分离肿瘤浸润淋巴细胞的装置及方法及其用途 |
| WO2021260186A1 (en) | 2020-06-26 | 2021-12-30 | Juno Therapeutics Gmbh | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
| WO2023196884A1 (en) | 2022-04-06 | 2023-10-12 | Juno Therapeutics, Inc. | Detection assay for human papillomavirus (hpv) type 16 (hpv-16) |
| EP4507704A1 (en) | 2022-04-15 | 2025-02-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1545204T3 (en) | 2002-09-06 | 2016-11-14 | The Government Of The Us Secretary Dept Of Health And Human Services | Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy |
| CN1609196A (zh) * | 2003-10-17 | 2005-04-27 | 上海普泛生物科技有限公司 | 用于发现肿瘤特异性抗原和肿瘤特异性抗原决定簇的高产率t淋巴细胞克隆技术 |
| AU2009214980B2 (en) * | 2008-02-11 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of obtaining antigen-specific T cell populations |
| US8383099B2 (en) * | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| CN102816734A (zh) * | 2012-05-09 | 2012-12-12 | 阮润生 | 一种肿瘤抗原特异性t细胞的获取方法 |
-
2014
- 2014-07-14 ES ES14745056T patent/ES2773548T3/es active Active
- 2014-07-14 CA CA2918080A patent/CA2918080A1/en active Pending
- 2014-07-14 AU AU2014290286A patent/AU2014290286A1/en not_active Abandoned
- 2014-07-14 ES ES19209253T patent/ES2932429T3/es active Active
- 2014-07-14 CN CN201480044285.7A patent/CN105452448B/zh active Active
- 2014-07-14 EP EP14745056.3A patent/EP3022294B1/en active Active
- 2014-07-14 CN CN202010606868.1A patent/CN111733131A/zh active Pending
- 2014-07-14 EP EP22197914.9A patent/EP4137564B1/en active Active
- 2014-07-14 WO PCT/US2014/046478 patent/WO2015009604A1/en not_active Ceased
- 2014-07-14 US US14/905,138 patent/US20160144018A1/en not_active Abandoned
- 2014-07-14 JP JP2016527005A patent/JP6616295B2/ja active Active
- 2014-07-14 ES ES22197914T patent/ES3034357T3/es active Active
- 2014-07-14 EP EP19209253.4A patent/EP3626817B1/en active Active
- 2014-07-14 RU RU2016103614A patent/RU2713333C2/ru active
-
2018
- 2018-12-13 US US16/218,658 patent/US20190117761A1/en not_active Abandoned
-
2019
- 2019-11-07 JP JP2019202239A patent/JP7315435B2/ja active Active
-
2020
- 2020-09-16 AU AU2020233702A patent/AU2020233702B2/en active Active
- 2020-12-07 US US17/113,570 patent/US11077182B2/en active Active
-
2021
- 2021-07-12 US US17/372,927 patent/US11376318B2/en active Active
- 2021-07-12 US US17/373,093 patent/US11331385B2/en active Active
- 2021-07-12 US US17/373,130 patent/US11338032B2/en active Active
-
2022
- 2022-06-13 US US17/838,662 patent/US11918640B2/en active Active
-
2023
- 2023-09-22 AU AU2023233209A patent/AU2023233209B2/en active Active
-
2024
- 2024-02-01 US US18/430,031 patent/US20240382577A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016524914A5 (cg-RX-API-DMAC7.html) | ||
| RU2016103614A (ru) | Способы получения т-клеток против антигена папилломавируса человека | |
| Welters et al. | Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine | |
| Tran et al. | Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy | |
| EP4289944A3 (en) | Method for preparing genetically-modified t cells which express chimeric antigen receptor | |
| JP2016509840A5 (cg-RX-API-DMAC7.html) | ||
| JP2012521215A5 (cg-RX-API-DMAC7.html) | ||
| MY180750A (en) | Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy | |
| IL273516B2 (en) | Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation | |
| JP2014087372A5 (cg-RX-API-DMAC7.html) | ||
| CN111902533A (zh) | 产生自然杀伤细胞的方法 | |
| Ge et al. | Potential biomarkers: Identifying powerful tumor specific T cells in adoptive cellular therapy | |
| Chen et al. | Blocking IL-10 signalling at the time of immunization renders the tumour more accessible to T cell infiltration in mice | |
| WO2019070435A8 (en) | Methods for selectively expanding cells expressing a tcr with a murine constant region | |
| TWI458485B (zh) | 毒殺型樹突細胞群組用於製備藥物的用途及包含其之醫藥組合物 | |
| Klein et al. | Restricted expression of EBV encoded proteins in in vitro infected CLL cells | |
| Galluzzi et al. | Rejuvenated T cells attack old tumors | |
| CN120796184A (zh) | 一种用于扩增多能干细胞来源的nk细胞的非细胞刺激剂 | |
| HK40038785A (en) | Methods of preparing anti-human papillomavirus antigen t cells | |
| Torisu-Itakura et al. | High IFNγ and perforin and low GM-CSF and sCD40L production correlate with CD8 TIL growth in breast cancer | |
| Mohs et al. | Blockage of CCL5/RANTES modifies immune infiltration and the inflammatory milieu during chronic liver disease: 65 | |
| HK40025869B (en) | Methods of preparing anti-human papillomavirus antigen t cells | |
| Cho et al. | CT7 (MAGE-C1)-Specific Cellular Immune Responses in the Bone Marrow Microenvironment of Multiple Myeloma Patients. | |
| Magg et al. | 349: Ethylenecarbodiimide (ECDI) Coupled Allogeneic Antigen Presenting Cells Induce Human CD4+ Regulatory T Cells | |
| Rangelova et al. | GENERATION OF TUMOR-INFILTRATING LYMPHOCYTES FROM PANCREATIC CANCER FOR CELLULAR THERAPY: HP015P |